Pfizer and Moderna are hustling to develop an mRNA bird flu vaccine, the same technology used in the companies' respective COVID-19 vaccines.

As of December 31, 2020Source: Biomedtracker, National Institutes of Health, Pharmapremia and AllianceBernstein (AB) A case ...

The FDA agreed for Novavax to continue trials of its vaccine combo after addressing a serious adverse event that paused ...

Australia’s audit office will probe the Morrison government’s $2 billion deal with US pharmaceutical giant Moderna to set up ...

Brad Miller, Moderna's CIO, has driven technology innovation to help drive continued gains for the roughly $7 billion revenue ...

Novavax cut its annual revenue forecast on Tuesday, citing lower-than-expected sales of its COVID-19 vaccine, ahead of ...

The number of COVID cases increased last week to 146. Cases had been falling in April and May and were as low as 31 at the ...

Population data was acquired from the California Department of ... dosages of the Pfizer-BioNTech vaccine. Other vaccines ...

The CDC recommends a single dose of any FDA-approved respiratory syncytial virus (RSV) vaccine for all adults ages 75 years ...

Also Read: DeSantis Administration Cautions Against Pfizer, Moderna mRNA Covid Vaccines for Vulnerable Individuals ... Novavax is scheduled to release its third-quarter earnings tomorrow, Tuesday.

Leerink Partners analyst Mani Foroohar assigned a Sell rating on Moderna (MRNA – Research Report) on November 7 and set a price target of ...